Mereo BioPharma...announces that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to navicixizumab for the treatment of high grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least 3 prior therapies and/or prior bevacizumab.